Favipiravir, Drugs Monitor, Page 2

(20 Nov 2020) Favipiravir- significant improvement in time to clinical cure

November 27, 2020

Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial https://doi.org/10.1016/j.ijid.2020.11.142 In this randomized, open-label, parallel-arm, multicenter, Phase 3 trial (CTRI/2020/05/025114), adults (18-75 years) with RT-PCR-confirmed COVID-19… Continue reading "(20 Nov 2020) Favipiravir- significant improvement in time to clinical cure"

(13 Nov 2020) Favipiravir, Interferon beta- no significant differences in clinical outcome in comparison to HCQ

November 20, 2020

Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia https://www.ijidonline.com/article/S1201-9712(20)32319-5/pdf A total of 89 patients underwent randomization with 49% (n = 44) assigned to favipiravir… Continue reading "(13 Nov 2020) Favipiravir, Interferon beta- no significant differences in clinical outcome in comparison to HCQ"

(01 Nov 2020) Favipiravir, Lopinavir/R- FPV found to be more beneficial in ICU patients compared to LPV/r

November 5, 2020

Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19 https://doi.org/10.1111/jcpt.13305 The aim of this study was to describe the clinical experience with FPV and LPV/r in critically ill patients with COVID-19… Continue reading "(01 Nov 2020) Favipiravir, Lopinavir/R- FPV found to be more beneficial in ICU patients compared to LPV/r"

(23 Sep 2020) Favipiravir- suppression in the erythrocyte series, no adverse effects in other hematologic parameters

September 26, 2020

The effects of favipiravir on hematological parameters of covid-19 patients. https://doi.org/10.1590/1806-9282.66.S2.65 Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively. The mean age of the patients receiving treatment with favipiravir was 63.7+/-12.3… Continue reading "(23 Sep 2020) Favipiravir- suppression in the erythrocyte series, no adverse effects in other hematologic parameters"

(10 Aug 2020) Favipiravir-viral clearance in 62.5% of patients within 4 days

August 19, 2020

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial https://doi.org/10.1093/cid/ciaa1176 In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment… Continue reading "(10 Aug 2020) Favipiravir-viral clearance in 62.5% of patients within 4 days"

(05 Aug 2020) Favipiravir- demonstrated rapid antiviral response against SARS-CoV-2

August 6, 2020

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial https://doi.org/10.1101/2020.07.26.20154724 In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment… Continue reading "(05 Aug 2020) Favipiravir- demonstrated rapid antiviral response against SARS-CoV-2"

(06 July 2020) Favipiravir – low mortality rate with combination treatment of favipiravir and nafamostat mesylate

July 7, 2020

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series https://doi.org/10.1186/s13054-020-03078-z This is the first report on nafamostat mesylate treatment in combination with favipiravir against Covid-19. No interruption of antiviral treatment occurred due to… Continue reading "(06 July 2020) Favipiravir – low mortality rate with combination treatment of favipiravir and nafamostat mesylate"

(01 July 2020) Favipiravir- 66.7%,Day-7 clinical improvement rate [53.7–78.0%]

July 6, 2020

Real-world Experience with Favipiravir for Treatment of COVID-19 in Thailand: Results from a Multi-center Observational Study https://doi.org/10.1101/2020.06.24.20133249 Among 247 COVID-19 patients, 63 (23.0%) received ≥1 dose of favipiravir. Of these, 27.0% required an O2−nasal cannula, 9.5% required non−invasive ventilation and/or… Continue reading "(01 July 2020) Favipiravir- 66.7%,Day-7 clinical improvement rate [53.7–78.0%]"

(01 June 2020) Favipiravir- Lower FPV serum concentrations in critically ill patients

June 2, 2020

Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19 https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1111/cts.12827 The serum concentration of FPV were measured using high-performance liquid chromatography in patients with severe COVID-19 who were admitted to the intensive care unit and placed on mechanical ventilation. The… Continue reading "(01 June 2020) Favipiravir- Lower FPV serum concentrations in critically ill patients"

(30 April 2020)Favipiravir – early viral clearance contributed to the improvement of chest imaging on Day 14

May 3, 2020

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study https://doi.org/10.1016/j.eng.2020.03.007 In this open-label comparative controlled study of patients with COVID-19, those treated with Favipiravir (FPV) appeared to have faster viral clearance and better chest imaging change on day 14… Continue reading "(30 April 2020)Favipiravir – early viral clearance contributed to the improvement of chest imaging on Day 14"

Tag: Favipiravir